Abstract

Glioblastoma (GBM) is the most common and aggressive brain tumor and is associated with poor prognosis. GBM cells are frequently resistant to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and finding new combinatorial therapies to sensitize glioma cells to TRAIL remains an important challenge. PIM kinases are serine/threonine kinases that promote cell survival and proliferation and are highly expressed in different tumors. In this work, we studied the role of PIM kinases as regulators of TRAIL sensitivity in GBM cells. Remarkably, PIM inhibition or knockdown facilitated activation by TRAIL of a TRAIL-R2/DR5-mediated and mitochondria-operated apoptotic pathway in TRAIL-resistant GBM cells. The sensitizing effect of PIM knockdown on TRAIL-induced apoptosis was mediated by enhanced caspase-8 recruitment to and activation at the death-inducing signaling complex (DISC). Interestingly, TRAIL-induced internalization of TRAIL-R2/DR5 was significantly reduced in PIM knockdown cells. Phospho-proteome profiling revealed a decreased phosphorylation of p62/SQSTM1 after PIM knockdown. Our results also showed an interaction between p62/SQSTM1 and the DISC that was reverted after PIM knockdown. In line with this, p62/SQSTM1 ablation increased TRAIL-R2/DR5 levels and facilitated TRAIL-induced caspase-8 activation, revealing an inhibitory role of p62/SQSTM1 in TRAIL-mediated apoptosis in GBM. Conversely, upregulation of TRAIL-R2/DR5 upon PIM inhibition and apoptosis induced by the combination of PIM inhibitor and TRAIL were abrogated by a constitutively phosphorylated p62/SQSTM1S332E mutant. Globally, our data represent the first evidence that PIM kinases regulate TRAIL-induced apoptosis in GBM and identify a specific role of p62/SQSTM1Ser332 phosphorylation in the regulation of the extrinsic apoptosis pathway activated by TRAIL.

Details

Title
PIM kinases mediate resistance of glioblastoma cells to TRAIL by a p62/SQSTM1-dependent mechanism
Author
Serrano-Saenz, Santiago 1 ; Palacios, Carmen 2 ; Delgado-Bellido, Daniel 3 ; López-Jiménez, Laura 3 ; Garcia-Diaz, Angel 3 ; Soto-Serrano, Yolanda 3 ; Ignacio, Casal J 4   VIAFID ORCID Logo  ; Bartolomé, Rubén A 4 ; Fernández-Luna, José Luis 5 ; López-Rivas Abelardo 2 ; Javier, Oliver F 1 

 CSIC, CIBERONC, Parque Tecnológico Ciencias de la Salud, Instituto de Parasitología y Biomedicina López-Neyra, Armilla, Spain (GRID:grid.4711.3) (ISNI:0000 0001 2183 4846) ; Carlos III Health Institute, Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427) 
 Carlos III Health Institute, Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427) ; CSIC-Universidad de Sevilla-Universidad Pablo de Olavide, CIBERONC, Centro Andaluz de Biología Molecular y Medicina Regenerativa-CABIMER, Sevilla, Spain (GRID:grid.427489.4) (ISNI:0000 0004 0631 1969) 
 CSIC, CIBERONC, Parque Tecnológico Ciencias de la Salud, Instituto de Parasitología y Biomedicina López-Neyra, Armilla, Spain (GRID:grid.4711.3) (ISNI:0000 0001 2183 4846) 
 Centro de Investigaciones Biológicas, CSIC, Department of Molecular Biomedicine, Madrid, Spain (GRID:grid.418281.6) (ISNI:0000 0004 1794 0752) 
 HUMV—Hospital Universitario Marqués de Valdecilla Avenida Valdecilla, 25, Santander, Spain (GRID:grid.411325.0) (ISNI:0000 0001 0627 4262) 
Publication year
2019
Publication date
Jan 2019
Publisher
Springer Nature B.V.
e-ISSN
20414889
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2175871580
Copyright
This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.